Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 657-663

  Johannsen, M ^a   Staehler, M ^b   Ohlmann, C H ^c   Florcken A ^a   Schmittel, A ^a   Otto, T ^d   Bex, A ^e   Hein, P ^a   Miller, K ^a   Weikert, S ^a   Grunwald V ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Department of Urology ^*  (Germany)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antiangiogenic treatment; Complete response; Discontinuation; Renal cell carcinoma; Targeted therapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR VACCINE;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE INTERVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; PANCREAS METASTASIS; PLEURA METASTASIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VISCERAL METASTASIS;

EID: 78649640201     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq437     Document Type: Article

References (22)

1. Rini BI, Campbell SC, Escudier B et al. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
3. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-3590.
4. Escudier B, Pluzanska A, Koralewski A et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
5. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
7. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase-III study. Lancet 2008; 372: 449-456.
8. Ljundberg B, Hanbury DC, Kuczyk M et al. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-1510.
9. Motzer RJ, Figlin RA, Olencki T et al. NCCN Practice Guidelines in Oncology-v.1. 2010 www.nccn.org (27 April 2010, date last accessed).
10. Brinkmann OA, Semik M, Gosherger G et al. The role of residual tumor resection in patients with metastatic renal cell carcinoma and partial remission following immunochemotherapy. Eur Urol Suppl 2007; 6: 641-645.
11. Rini B, Shaw V, Rosenberg JE et al. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 2006; 5(3): 232-234.
12. Johannsen M, Flörcken A, Bex A et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicenter retrospective analysis. Eur Urol 2009; 55(6): 1430-1438.
13. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
14. Johannsen M, Brinkmann OA, Bergmann L et al. The role of cytokine therapy in metastatic renal cell cancer. Eur Urol Suppl 2007; 6: 658-664.
15. Mancuso M, Davis R, Norberg S et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
16. Jain R, Tong R, Munn L et al. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67: 2729-2735.
17. Rothermundt CA, Omlin A, Gillessen S et al. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer. Ann Oncol 2009; 20(6): 1144-1146.
18. Ebos JML, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
19. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
20. Heng DY, Rini B, Garcia J et al. Prolonged complete responses and nearcomplete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 446-451.
21. Neill MG, Wei AC, Jewett MAS et al. Consolidative renal cell carcinoma metastasectomy for partial response after multitargeted tyrosine kinase inhibitor therapy. Urology 2007; 70: 178.e9-178.e11.
22. Staehler M, Haseke N, Zilinberg E et al. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 2010; 28(2): 139-144.